Similar articles

• Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand.

  Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Oster P, et al. Vaccine. 2007 Apr 20;25(16):3075-9. doi: 10.1016/j.vaccine.2007.01.023. Epub 2007 Jan 22. Vaccine. 2007. PMID: 17289223
• Re: Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease, Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Vaccine 2007;25(16):3080-4.

  Lennon D. Lennon D. Vaccine. 2007 Sep 28;25(39-40):6833; author reply 6833-4. doi: 10.1016/j.vaccine.2007.06.024. Epub 2007 Jun 21. Vaccine. 2007. PMID: 17630051 No abstract available.
• Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.

  Wedege E, Bolstad K, Aase A, Herstad TK, McCallum L, Rosenqvist E, Oster P, Martin D. Wedege E, et al. Clin Vaccine Immunol. 2007 Jul;14(7):830-8. doi: 10.1128/CVI.00039-07. Epub 2007 May 9. Clin Vaccine Immunol. 2007. PMID: 17494638 Free PMC article. Clinical Trial.
• Recent developments in vaccines to prevent meningococcal serogroup B infections.

  Vermont CL, van den Dobbelsteen GP, de Groot R. Vermont CL, et al. Curr Opin Mol Ther. 2003 Feb;5(1):33-8. Curr Opin Mol Ther. 2003. PMID: 12669468 Review.
• Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand.

  Lennon D, Jackson C, Wong S, Horsfall M, Stewart J, Reid S. Lennon D, et al. Clin Infect Dis. 2009 Aug 15;49(4):597-605. doi: 10.1086/603552. Clin Infect Dis. 2009. PMID: 19622040 Review.